



OCT - 6 2005

Office of Regulatory Policy  
HFD - 13  
5600 Fishers Lane,  
Rockville, MD 20857

Attention: Claudia Grillo

Dear Ms. Axelrad:

The attached application for patent term extension of U.S. Patent No. 5,981,576 was filed on September 16, 2004, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application, PREVICOX® (firocoxib), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7744 (telephone) or (571)273-7744 (facsimile).

Karin Ferriter  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Mitul I. Desai  
Merck & Co., Inc.  
Patent Department  
PO Box 2000  
Rahway, NJ 07065-0907